The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

Although pembrolizumab has shown clinical benefit in patients with small-cell lung cancer (SCLC), its actual efficacy in combination with a conventional chemotherapy drug has not been determined. We performed ...

Source: World Journal of Surgical Oncology - October 14, 2021 Category: Cancer & Oncology Authors: Qiangyun Liu, Yixuan Zhang, Miaowen Liu, Ruoxin Xu, Fengming Yi, Yiping Wei, Shuqiang Zhu and Wenxiong Zhang Tags: Review Source Type: research